Experts say new PHARMAC funding could help avert potential public health ‘time bomb’
View the press release
See the PHARMAC release.
ASHM "Chronic Hepatitis B – is there such a thing as a “healthy carrier”?" See article.
Journal of Hepatology 50 (2009) 227–242
"EASL Clinical Practice Guidelines:Management of chronic hepatitis B"
European Association for the Study of the Liver
Read full article.
The New England Journal of Medicine
"Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B".
The results at Week 48.
Read full article.
From ENDONURSE.COM
New data show that a significant number of patients with chronic hepatitis B virus
infection who received PEGASYS® (peginterferon alfa-2a) treatment achieved clearance
of a blood antigen known as hepatitis B s-antigen (HBsAg). Clearance of this marker is
associated with favourable clinical outcomes, and is as close to a cure as possible in
this disease. HBsAg clearance shows that an individual's own immune system is able to
control the infection. None of the nucleoside/nucleotide analogue treatments for
hepatitis B virus (HBV) have shown such a result.
Read full article.
From theaustralian.news.com.au
Hepatitis B experts at loggerheads
POOR prescribing habits by liver specialists are creating resistance to the first drugs
able to combat the serious side effects of hepatitis B. And unless doctors modify their
ways, the same thing will happen to drugs introduced to replace them.
Read full article.